Smoke-Free Alternatives Trade Association and Coalition of Vapor Businesses & State Associations Granted Motion to Intervene in American Association of Pediatrics v FDA

WASHINGTON, Oct. 4, 2019 /PRNewswire/ — On October 2, 2019, Paul W. Grimm, Judge of the United States District Court, District of Maryland issued his decision via Letter Order in the American Association of Pediatrics v. the FDA.

What the Judge Wrote:

“I will grant the Vapor Associations’ Motion to intervene exclusively for the limited purpose of filing an appeal of the May 15, 2019 Memorandum.

“Here, the businesses represented by the Vapor Associations manufacture and sell the e-cigarette products at issue in this case. Therefore, they are subject to the FDA’s PMTA requirements and they will be directly affected by the filing deadlines, which could impact sales that otherwise would be possible without the Remedy Order’s accelerated deadline, if the businesses and manufacturers are not able to meet the deadline and obtain approval for their sales.

“Thus, I am persuaded that the Vapor Associations have shown that they have standing and a protectable interest that justifies their intervention for the limited purpose of appealing my final rulings, as the Remedy Order affects the FDA regulations that control the businesses’ activities and ability to profit in the vapor industry.

“Further, they claim that the accelerated deadlines in the Remedy Order would be devastating to their industry, and the Government is moving toward enforcement rather than protecting their interests. The Vapor Associations have demonstrated that they should be permitted to intervene as of right. See id.; Fed. R. Civ. P. 24(a)(2). Their Motion to Intervene is granted exclusively for the limited purpose of filing an appeal of the May 15, 2019 Memorandum Opinion and Order and the Remedy Order and for no other purpose.”

What it Means:

While he did not grant the Vapor Associations’ Motion to Stay the 10-month deadline decision, the Associations are now parties to the litigation, can appeal the entire case – and move to stay the PMTA deadline – with the Fourth Circuit Court of Appeals. 

About SFATA: SFATA is the premier and largest vapor and e-cig trade association. The association represents the interests of the entire supply chain, including manufacturers, online retailers, brick and mortar vapor store, distributors, importers, and wholesalers. For more information about SFATA, visit https://www.sfata.org and follow SFATA on Facebook, Twitter, Instagram.

Contact: Amy Krakow, 212.587.0540

View original content to download multimedia:http://www.prnewswire.com/news-releases/smoke-free-alternatives-trade-association-and-coalition-of-vapor-businesses–state-associations-granted-motion-to-intervene-in-american-association-of-pediatrics-v-fda-300931502.html

SOURCE Smoke-Free Alternatives Trade Association (SFATA)

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago